Secondary analysis of 617 patients with newly diagnosed multiple myeloma in the phase III GMMG-HD7 trial: serum mass spectrometry negativity was associated with longer progression-free survival, strongest after 12 months of maintenance (HR 0.25, 95% CI 0.15–0.43).
Secondary analysisn = 617
Jin et al. Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial